论文部分内容阅读
为观察尤瑞克林与奥扎格雷钠联合应用治疗急性脑梗死的近期临床疗效及安全性,将80例急性脑梗死住院患者分为2组:联合组39例,对照组41例。两组均予以奥扎格雷钠氯化钠注射液(80 mg,2/d)治疗,联合组加用尤瑞克林治疗(0.15 PNAU,1/d),疗程14天后评定美国国立卫生研究院卒中量表(NIHSS)改善程度、临床疗效及不良反应。结果表明,联合组总体、部分前循环亚组、后循环梗死亚组和中度脑梗死患者NIHSS评分改善程度优于相应对照组(P<0.05),腔隙性梗死亚组和轻度脑梗死患者NIHSS评分改善程度与相应对照组没有统计学差异(P>0.05)。部分前循环梗死及中度脑梗死患者中,联合组显效率与对照组比较差异有统计学意义(P<0.05)。联合组中2例患者出现不良反应(5.1%),表现为心慌、大汗、腹泻或血压下降。结论:尤瑞克林与奥扎格雷钠联合应用治疗轻/中度急性脑梗死患者是安全的,有附加疗效。
To observe the clinical efficacy and safety of uracil and ozagrel sodium in the treatment of acute cerebral infarction, 80 inpatients with acute cerebral infarction were divided into two groups: 39 in combination group and 41 in control group. Both groups were treated with ozagrel sodium and sodium chloride injection (80 mg, 2 / d), combined with urelin (0.15 PNAU, 1 / d), and after 14 days of treatment, the National Institutes of Health Stroke Scale (NIHSS) improvement, clinical efficacy and adverse reactions. The results showed that the NIHSS scores of the combined group, partial anterior circulation subgroup, posterior circulation infarction subgroup and moderate cerebral infarction group were better than that of the corresponding control group (P <0.05), lacunar infarct subgroup and mild cerebral infarction There was no significant difference in NIHSS scores between the two groups (P> 0.05). Part of the anterior circulation infarction and moderate cerebral infarction patients, the combined group markedly effective rate compared with the control group was statistically significant (P <0.05). Adverse reactions (5.1%) occurred in 2 patients in the combination group with palpitation, sweating, diarrhea, or decreased blood pressure. Conclusions: The combination of urelin and ozagrel sodium for the treatment of patients with mild to moderate acute cerebral infarction is safe and has an additional therapeutic effect.